VRAY - ViewRay, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

ViewRay, Inc.

2 Thermo Fisher Way
Oakwood, OH 44146
United States

IndustryMedical Devices
Full Time Employees221

Key Executives

NameTitlePayExercisedYear Born
Mr. Scott William DrakePres, CEO & Director770.08kN/A1968
Mr. Shahriar MatinChief Operating Officer526.46kN/A1975
Mr. James AlecxihChief Commercial Officer315kN/A1965
Mr. Brian KnaleyInterim Chief Financial OfficerN/AN/A1970
Dr. James F. DempseyChief Scientific Officer & DirectorN/AN/A1971
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image-guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. ViewRay, Inc. serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. The company markets its MRIdian through a direct sales force in North America. ViewRay, Inc. has collaboration agreements with Elekta AB and Medtronic. The company was founded in 2004 and is headquartered in Oakwood, Ohio.

Corporate Governance

ViewRay, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.